Hi, help us enhance your experience
Hi, help us enhance your experience
Hi, help us enhance your experience
1457 Views
Dr KK Aggarwal 03 January 2021
With input from Dr Monica Vasudev
1274: COVID-19 Vaccines
[Source: Medscape; Reproduced for educational purposes]
Table 1. Vaccine platform attributes
Platform | Attributes | Doses | Vaccine Candidate (Manufacturer) |
mRNA | Fast development speed; low- to-medium manufacturing scale | 2 | BNT-162b2 (Pfizer- BioNTech); mRNA-1273 (Moderna) |
DNA | Fast development speed; medium manufacturing scale | 2 | INO-4800 (Inovio) |
Viral vector | Medium development; high manufacturing scale | 1 or 2 | AZA-1222 Ad5-CoV (AstraZeneca- Oxford University); Ad26.COV2.S (Johnson & Johnson) |
Protein subunit | Medium- to-fast development; high manufacturing scale | 2 | NVX-CoV2373 (Novavax) |
Dr KK Aggarwal
President CMAAO, HCFI and Past National President IMA
{{Article_Title}}
{{Article_Author}}
{{Article_Title}}
{{Article_Author}}